Podcast
GI Insights
Hosted by ReachMD · EN
Looking to digest the latest in gastroenterology? GI Insights is here to provide updates on screening guidelines, diagnostic options, and management tools for all diseases and disorders affecting the gastrointestinal tract.
20episodes
Episodes
Newest firstAll episodes
Screening Modalities for Colon Cancer: What You Need to Know
May 2900:11:00Tap to summarizeHost: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.
Transcribe →Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR
May 2900:12:15Tap to summarizeHost: Peter Buch, MD, FACG, AGAF, FACP Guest: Vivek Kaul, MD The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.
Transcribe →Strategies for Increasing Colorectal Cancer Screening Rates
Apr 3000:09:00Tap to summarizeHost: Neilanjan Nandi, MD Guest: Samir Shah, MD From new guideline recommendations to a concert featuring the American College of Gastroenterology’s official band, a lot is being done to help raise awareness of the importance of screening for colorectal cancer. So how can you help increase screening rates in your own community? Get inspired with these creative initiatives shared by Dr. Neil Nandi and Dr. Samir Shah, President of the American College of Gastroenterology.
Transcribe →Adenoma Detection Rate: A Prediction of Colorectal Cancer
Apr 3000:13:30Tap to summarizeHost: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH Adenoma detection rate (ADR) may help us better detect our patients’ risk of developing colorectal cancer. To explore what we need to know about this quality indicator, Dr. Peter Buch joins Dr. Aasma Shaukat from the New York University Grossman School of Medicine to talk about ADR.
Transcribe →Assessing Racial Disparities in Colorectal Cancer Screening
Apr 3000:14:30Tap to summarizeHost: Neilanjan Nandi, MD Guest: Folasade P. May, MD, PhD, MPhil Racial and ethnic bias prevent patients with colorectal cancer from receiving the highest quality of care. Dr. Neil Nandi is joined by Dr. Fola May, Assistant Professor of Medicine at UCLA, to discuss racial inequalities in access to care and screening for patients with colorectal cancer.
Transcribe →Recapping the 2021 ACG Clinical Guidelines: What’s New in Colorectal Cancer Screening?
Apr 3000:13:00Tap to summarizeHost: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH Screening for colorectal cancer is unique because there are several screening options available. So how can we balance the latest ACG Clinical Guidelines with patient preferences, cultural context, and insurance coverage to find the best screening option for our patients? Joining Dr. Peter Buch to discuss the updated recommendations is Dr. Aasma Shaukat, lead author of the 2021 ACG Clinical Guidelines for colorectal cancer screening.
Transcribe →Developments in Colorectal Cancer Screening: Cell-Free DNA Blood Testing
Apr 3000:10:30Tap to summarizeHost: Peter Buch, MD, FACG, AGAF, FACP Guest: William Grady, MD While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.
Transcribe →Colorectal Cancer in Young Patients: A Multidisciplinary Approach
Apr 3000:12:00Tap to summarizeHost: Peter Buch, MD, FACG, AGAF, FACP Guest: David Liska, MD Since the 1990s, clinicians have been seeing a significant increase in colorectal cancer among young patients, who are under the age of 50. A multidisciplinary approach is key as diagnostic and treatment considerations are specific to their age. Dive in with Dr. Peter Buch as he’s joined by Dr. David Liska, Section Chief of Oncology in the Department of Colorectal Surgery at the Cleveland Clinic.
Transcribe →Making the Right Choices for Patients with Ulcerative Colitis
Jan 2200:14:15Tap to summarizeHost: Peter Buch, MD, FACG, AGAF, FACP Guest: David P. Hudesman, MD Ulcerative colitis treatment continues to evolve with a growing range of targeted therapies, from S1P modulators to JAK inhibitors. Joining Dr. Peter Buch to discuss how clinicians can personalize care based on disease severity, safety profiles, and patient response is Dr. David Hudesman. He's a Professor in the Department of Medicine at NYU Grossman School of Medicine and the Director of NYU Langone’s Inflammatory Bowel Disease Center.
Transcribe →Advances in Parenteral Nutrition: Examining Multi-Source Lipid Emulsions
Dec 1900:07:15Tap to summarizeHost: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Cogle, PharmD, BCNSP, FASPEN Evolving evidence supports the shift from single-source to multi-source intravenous lipid emulsions in parenteral nutrition. These newer formulations may offer improved metabolic, inflammatory, and hepatic outcomes, particularly for vulnerable patient populations. Joining Dr. Charles Turck to discuss the clinical rationale and operational considerations for these formulations is Dr. Sarah Cogle, who’s a Clinical Pharmacist Specialist at Vanderbilt University Medical Center in Nashville, Tennessee.
Transcribe →